From transthyretin cardiac amyloidosis diagnosis to tafamidis treatment: Association of drop-off with patient sociodemographic characteristics
Walenczyk K, Singh A, Tong K, Burg M, Miller E. From transthyretin cardiac amyloidosis diagnosis to tafamidis treatment: Association of drop-off with patient sociodemographic characteristics. American Journal Of Health-System Pharmacy 2024, zxae183. PMID: 38963826, DOI: 10.1093/ajhp/zxae183.Peer-Reviewed Original ResearchPatient sociodemographic characteristicsATTR-CASociodemographic characteristicsSpecialty pharmacyPyrophosphate scintigraphyPopulation prevalence ratesEconomically disadvantaged areasTransthyretin cardiac amyloidosisBlack/African American raceReduce disparitiesPotential patient subgroupsPharmacy processesProportion of daysClinical pathwayCompare sociodemographicsDisadvantaged areasEquitable provisionTafamidis therapyCardiac amyloidosisTafamidis treatmentPrevalence ratesClinical programsAmerican racePatient subgroupsPosting manuscripts